TABLE OF CONTENTS
Volume 22, Issue 5 (May 2008)
Meeting report |
Spotlight Reviews |
Reviews |
Original Articles |
Letters to the Editor
Editorial
Therapy-related acute myeloid leukaemia with mutated NPM1: treatment induced or de novo in origin?
B Falini
Leukemia 22: 891-892; doi:10.1038/leu.2008.44
Meeting report
Meeting report: myelodysplastic syndromes at ASH 2007
R Itzykson, C Gardin and P Fenaux
Leukemia 22: 893-897; advance online publication, March 6, 2008; doi:10.1038/leu.2008.45
Spotlight Reviews
Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis
E K Thomas, J A Cancelas, Y Zheng and D A Williams
Leukemia 22: 898-904; advance online publication, March 20, 2008; doi:10.1038/leu.2008.71
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders
F Cervantes, F Passamonti and G Barosi
Leukemia 22: 905-914; advance online publication, April 3, 2008; doi:10.1038/leu.2008.72
Reviews
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
A Renneville, C Roumier, V Biggio, O Nibourel, N Boissel, P Fenaux and C Preudhomme
Leukemia 22: 915-931; advance online publication, February 21, 2008; doi:10.1038/leu.2008.19
Experimental non-ATP-competitive therapies for chronic myelogenous leukemia
A Quintás-Cardama
Leukemia 22: 932-940; advance online publication, March 6, 2008; doi:10.1038/leu.2008.47
The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites
Y Shiozawa, A M Havens, K J Pienta and R S Taichman
Leukemia 22: 941-950; advance online publication, February 28, 2008; doi:10.1038/leu.2008.48
Original Articles
Acute Leukemias
NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features
M T Andersen, M K Andersen, D H Christiansen and J Pedersen-Bjergaard
Leukemia 22: 951-955; advance online publication, February 14, 2008; doi:10.1038/leu.2008.17
Expression of myeloperoxidase enhances the chemosensitivity of leukemia cells through the generation of reactive oxygen species and the nitration of protein
Y Sawayama, Y Miyazaki, K Ando, K Horio, C Tsutsumi, D Imanishi, H Tsushima, Y Imaizumi, T Hata, T Fukushima, S Yoshida, Y Onimaru, M Iwanaga, J Taguchi, K Kuriyama and M Tomonaga
Leukemia 22: 956-964; advance online publication, February 14, 2008; doi:10.1038/leu.2008.8
Chronic Myeloproliferative Disorders
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
A Quintás-Cardama, W Tong, H Kantarjian, D Thomas, F Ravandi, S Kornblau, T Manshouri, J E Cortes, G Garcia-Manero and S Verstovsek
Leukemia 22: 965-970; advance online publication, April 3, 2008; doi:10.1038/leu.2008.91
Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells
E Bonhoure, A Lauret, D J Barnes, C Martin, B Malavaud, T Kohama, J V Melo and O Cuvillier
Leukemia 22: 971-979; advance online publication, April 10, 2008; doi:10.1038/leu.2008.95
Chronic Lymphocytic Leukemia
Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division
A Poggi, S Catellani, A Bruzzone, F Caligaris-Cappio, M Gobbi and M R Zocchi
Leukemia 22: 980-988; advance online publication, February 21, 2008; doi:10.1038/leu.2008.21
Minimal Risidual Disease
Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?
E Fronkova, E Mejstrikova, S Avigad, K W Chik, L Castillo, S Manor, L Reznickova, T Valova, K Zdrahalova, O Hrusak, Y Jabali, M Schrappe, V Conter, S Izraeli, C K Li, B Stark, J Stary and J Trka
Leukemia 22: 989-997; advance online publication, February 28, 2008; doi:10.1038/leu.2008.22
Immunology
NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G
G Maki, G M Hayes, A Naji, T Tyler, E D Carosella, N Rouas-Freiss and S A Gregory
Leukemia 22: 998-1006; advance online publication, February 21, 2008; doi:10.1038/leu.2008.15
Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response
I Hus, M Schmitt, J Tabarkiewicz, S Radej, K Wojas, A Bojarska-Junak, A Schmitt, K Giannopoulos, A Dmoszy
ska and J Roliski
Leukemia 22: 1007-1017; advance online publication, March 6, 2008; doi:10.1038/leu.2008.29
Differentiation
hNUDC promotes the cell proliferation and differentiation in a leukemic cell line via activation of the thrombopoietin receptor (Mpl)
Y-S Tang, Y-P Zhang and P Xu
Leukemia 22: 1018-1025; advance online publication, February 21, 2008; doi:10.1038/leu.2008.20
Lymphoma
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas
S Balasubramanian, J Ramos, W Luo, M Sirisawad, E Verner and J J Buggy
Leukemia 22: 1026-1034; advance online publication, February 7, 2008; doi:10.1038/leu.2008.9
DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status
B L Pike, T C Greiner, X Wang, D D Weisenburger, Y-H Hsu, G Renaud, T G Wolfsberg, M Kim, D J Weisenberger, K D Siegmund, W Ye, S Groshen, R Mehrian-Shai, J Delabie, W C Chan, P W Laird and J G Hacia
Leukemia 22: 1035-1043; advance online publication, February 21, 2008; doi:10.1038/leu.2008.18
Myeloma
Genetic aberrations and survival in plasma cell leukemia
R E Tiedemann, N Gonzalez-Paz, R A Kyle, R Santana-Davila, T Price-Troska, S A Van Wier, W J Chng, R P Ketterling, M A Gertz, K Henderson, P R Greipp, A Dispenzieri, M Q Lacy, S V Rajkumar, P L Bergsagel, A K Stewart and R Fonseca
Leukemia 22: 1044-1052; advance online publication, January 24, 2008; doi:10.1038/leu.2008.4
Letters to the Editor
MT1-MMP as a downstream target of BCR-ABL/ABL interactor 1 signaling: polarized distribution and involvement in BCR-ABL-stimulated leukemic cell migration
X Sun, Y Li, W Yu, B Wang, Y Tao and Z Dai
Leukemia 22: 1053-1056; advance online publication, October 18, 2007; doi:10.1038/sj.leu.2404990
Mature B-cell lymphoblastic leukemia with MLL rearrangement: an uncommon and distinct subset of childhood acute leukemia
N Blin, F Méchinaud, P Talmant, R Garand, P Boutard, N Dastugue, E A McIntyre, J L Harousseau and H Avet-Loiseau
Leukemia 22: 1056-1059; advance online publication, November 15, 2007; doi:10.1038/sj.leu.2404992
Chronic myeloproliferative diseases with concurrent BCR–ABL junction and JAK2V617F mutation
K Hussein, O Bock, K Theophile, A Seegers, H Arps, O Basten, K-H Grips, J Franz-Werner, G Büsche and H Kreipe
Leukemia 22: 1059-1062; advance online publication, November 1, 2007; doi:10.1038/sj.leu.2404993
Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L
M Christopeit, M Schendel, J Föll, L P Müller, G Keysser and G Behre
Leukemia 22: 1062-1064; advance online publication, November 1, 2007; doi:10.1038/sj.leu.2404996
Characterization of three t(3;8)(q27;q24) translocations from diffuse large B-cell lymphomas
P Bertrand, C Maingonnat, J M Picquenot, N Dastugue, D Penther, L Ysebaert, C Maisonneuve, H Tilly and C Bastard
Leukemia 22: 1064-1067; advance online publication, November 8, 2007; doi:10.1038/sj.leu.2404999
Downregulation of microRNA-142 by proto-oncogene LMO2 and its co-factors
W Yuan, W Sun, S Yang, J Du, C-L Zhai, Z-Q Wang, J Zhang and T-H Zhu
Leukemia 22: 1067-1071; advance online publication, November 1, 2007; doi:10.1038/sj.leu.2405001
Spectrum of p53 mutations in low-grade B-cell malignancies
T Bromidge, S Johnson and D Howe
Leukemia 22: 1071-1073; advance online publication, November 8, 2007; doi:10.1038/sj.leu.2405002
V
genes in chronic lymphocytic leukaemia: highly skewed V gene segment usage with similar CDR3 sequences
A Abusedra, R Joshi, A Bybee, J F Apperley and S D Wagner
Leukemia 22: 1073-1075; advance online publication, November 1, 2007; doi:10.1038/sj.leu.2405003
Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD
H-A Hou, W-C Chou, L-I Lin, C-Y Chen, J-L Tang, M-H Tseng, C-F Huang, R-J Chiou, F-Y Lee, M-C Liu and H-F Tien
Leukemia 22: 1075-1078; advance online publication, November 1, 2007; doi:10.1038/sj.leu.2405005
Childhood T-cell non-Hodgkin's lymphoma, colorectal carcinoma and brain tumor in association with café-au-lait spots caused by a novel homozygous PMS2 mutation
C P Kratz, C M Niemeyer, E Jüttner, M Kartal, A Weninger, A Schmitt-Graeff, U Kontny, M Lauten, S Utzolino, J Rädecke, C Fonatsch and K Wimmer
Leukemia 22: 1078-1080; advance online publication, November 15, 2007; doi:10.1038/sj.leu.2405008
Do 
2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy?
W J Chng, S Jacobus and R Fonseca
Leukemia 22: 1080-1081; advance online publication, November 29, 2007; doi:10.1038/sj.leu.2405009
Rituximab in CD20 positive multiple myeloma
J M Bergua, C Cabrera, E G Arteta and J Prieto
Leukemia 22: 1082-1083; advance online publication, November 1, 2007; doi:10.1038/sj.leu.2405010
Reply to 'Rituximab activity in CD20-positive multiple myeloma'
A Gozzetti, A Fabbri, S Lazzi, M Bocchia and F Lauria
Leukemia 22: 1083; advance online publication, November 1, 2007; doi:10.1038/sj.leu.2405011
Reply to Gozzetti et al.
J M Bergua, C Cabrera, E G Arteta and J Prieto
Leukemia 22: 1083-1084; advance online publication, November 1, 2007; doi:10.1038/sj.leu.2405012
Tumor-derived IL-6 may contribute to the immunological defect in CLL
A G S Buggins, P E M Patten, J Richards, N S B Thomas, G J Mufti and S Devereux
Leukemia 22: 1084-1087; advance online publication, November 1, 2007; doi:10.1038/sj.leu.2405015
The hDMP1 tumor suppressor is a new WT1 target in myeloid leukemias
M P Tschan, U Gullberg, D Shan, B E Torbett, M F Fey and A Tobler
Leukemia 22: 1087-1090; advance online publication, November 1, 2007; doi:10.1038/sj.leu.2405018
is able to maintain complete molecular remission induced by imatinib after its discontinuation